Universal Electronics’ Eterna Remote Named as CES 2023 Innovation Awards Honoree
Universal Electronics Inc. (NASDAQ: UEIC), the worldwide leader in universal control technology for entertainment and smart home devices today announced that it has been named a CES® 2023 Innovation Awards Honoree for its UEI Eterna remote control. This year’s CES Innovation Awards program received a record-high number of over 2100 submissions. The announcement was made ahead of CES 2023, the world’s most influential technology event, happening Jan. 5-8 in Las Vegas, NV.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221222005096/en/
UEI's Eterna Remote Receives the CES 2023 Innovation Award (Graphic: Business Wire)
Maximum performance with minimum battery waste
Targeting TV service providers that want to minimize their carbon footprint and battery waste without compromising on the consumer experience, UEI has designed and developed its most advanced and sustainable voice remote-control platform ever.
The UEI Eterna family of products are built with UEI’s new Xtreme Low-Power Bluetooth LE silicon making them 2.5 times more powerful and up to 10 times more efficient than the previous generation of voice remote controls. In combination with a revolutionary high-density photovoltaic panel that harvests three times more energy than traditional panels, it can self-power despite intense usage or in low light conditions.
For better accessibility in the dark, the UEI Eterna line supports Ambient-Aware backlighting. The backlight activates when there is insufficient lighting in the room. This further reduces power consumption to a bare minimum. UEI Eterna is built with recycled and recyclable materials and packaged free of single-use plastics (SUP). To facilitate refurbishment and recycling programs, the products are specifically designed for easy disassembly which helps to minimize waste and maximize the re-use of field returned units.
“With sustainability as a driving force for product innovation and design at UEI, we are delighted that our UEI Eterna product received this award,” said Menno Koopmans, SVP of Global Sales and Marketing. “The UEI Eterna remote is the first of its kind that delivers on our customers’ sustainability goals without having to compromise on user experience or product features. This innovation is a clear milestone on our journey towards a battery-less world.”
The UEI Eterna and UEI Eterna XLR also feature a unique Interactive Light Bar that communicates its status in real-time with the end user using distinct and recognizable light patterns.
The product line comes with a unique pre-integrated support system that enhances its sustainability performance as it minimizes customer service calls or related truck rolls:
- Powered by QuickSet® Cloud, it supports UEI’s unique and widely adopted automated discovery and set-up capability to pair the set-top-box remote with the customer’s TV, soundbar or audio system. In 2022 alone, QuickSet is estimated to have saved UEI’s existing pay TV customers over 4 million man-hours of programming time.
- It is supported by UEI’s Virtual Agent that provides self-help capabilities during installation, feature discovery and troubleshooting, and is available on both the TV screen and the mobile device.
- It comes with the turnkey white label My Nevo Companion App to enable the setup and support via a mobile device, customize the user preferences, and optimize power management.
- UEI’s new plug-and-play SDK facilitates easy and trouble-free integration with Android TV set-top boxes.
The UEI Eterna family of products is developed for Android TV and RDK operating systems and is scheduled to be available by the end of the first quarter of 2023.
To schedule a press tour or demo please visit here, or come by our booth #52014 at the Venetian Expo at CES taking place in Las Vegas on January 5-8.
About the CES Innovations Award
The CES Innovation Awards program is an annual competition honoring outstanding design and engineering in 28 consumer technology product categories. Those with the highest rating receive the “Best of Innovation” distinction. An elite panel of industry expert judges, including members of the media, designers, engineers and more, reviewed submissions based on innovation, engineering and functionality, aesthetics and design.
About Universal Electronics
Universal Electronics Inc. (NASDAQ:UEIC), Universal Electronics Inc. (NASDAQ: UEIC), the global leader in wireless universal control solutions for home entertainment and smart home devices; designs, develops, manufactures, ships and supports hardware and software control and sensor technology solutions. UEI partners with many Fortune 500 customers, including Comcast, Vivint Smart Home, Samsung, LG, Sony, and Daikin to serve video, telecommunications, security service providers, television, smart home, and HVAC system manufacturers. For over 35 years, UEI has been pioneering breakthrough innovations such as voice control and QuickSet cloud, the world’s leading platform for automated set-up and control of devices in the home. For more information visit www.uei.com
Safe Harbor Statement
This press release contains forward-looking statements that are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development, delivery, technical performance, and market acceptance of products and technologies identified in this release; the purchasing by UEI customers of the UEI ETERNA products identified in this release in the quantities anticipated by management; the adoption of the energy harvesting and low power technologies identified in this release by UEI customers, the continued penetration and growth of UEI low power, energy harvesting, and other products and consumer technologies identified in this release; and other factors described in UEI’s filings with the Securities and Exchange Commission. The actual results that UEI achieves may differ materially from any forward-looking statement due to such risks and uncertainties. UEI undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221222005096/en/
Contact information
Company Contact
Eva Delgado
Universal Electronics Inc.
eva.delgado@uei.com
714-987-8209
Agency Contact
Stephanie Quinn
Kiterocket
squinn@kiterocket.com
480-316-8370
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom